Phase 3 Hemophilia A trials in Malaysia: Trial Insights

Filters: Condition: Hemophilia A Phase: Phase 3 Country / region: Malaysia Clear all

24 trials match Source: ClinicalTrials.gov registrations

Trials started per year
Category	Trials
2009	2
2010	1
2012	2
2013	2
2014	4
2015	2
2018	5
2019	1
2021	1
2022	1
2023	1
2024	1
2026	1

Trials by status
Category	Trials
Completed	20
Active, not recruiting	2
Not yet recruiting	1
Terminated	1

Top lead sponsors
Category	Trials
Novo Nordisk A/S	12
Baxalta now part of Shire	4
Genzyme, a Sanofi Company	4
CSL Behring	2
Hoffmann-La Roche	1
Laboratoire français de Fractionnement et de Biotechnologies	1

Top conditions
Category	Trials
Hemophilia A	24
Blood Coagulation Disorders	2
Blood Coagulation Disorders, Inherited	2
Coagulation Protein Disorders	2
Genetic Diseases, Inborn	2
Genetic Diseases, X-Linked	2
Hematologic Diseases	2
Hemophilia B	2
Hemorrhagic Disorders	2

Trials

Showing 1 to 24 of 24. Each trial links to its page on Pharma Observatory.

A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A NCT07830732Phase 3Not yet recruitingNovo Nordisk A/SStarted 2026
Safety and Efficacy of FVIIa to Prevent Excessive Bleeding in Hemophilia Patients With Inhibitors Undergoing Major Surgery NCT05695391Phase 3TerminatedLaboratoire français de Fractionnement et de BiotechnologiesStarted 2024
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A NCT05685238Phase 3Active, not recruitingNovo Nordisk A/SStarted 2023
A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors NCT05135559Phase 3Active, not recruitingNovo Nordisk A/SStarted 2022
A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors NCT05053139Phase 3CompletedNovo Nordisk A/SStarted 2021
Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX NCT03754790Phase 3CompletedGenzyme, a Sanofi CompanyStarted 2019
A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis NCT03549871Phase 3CompletedGenzyme, a Sanofi CompanyStarted 2018
A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A NCT03528551Phase 3CompletedNovo Nordisk A/SStarted 2018
Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants NCT03315455Phase 3CompletedHoffmann-La RocheStarted 2018
A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors NCT03417245Phase 3CompletedGenzyme, a Sanofi CompanyStarted 2018
A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors NCT03417102Phase 3CompletedGenzyme, a Sanofi CompanyStarted 2018
BAX 855 PK-guided Dosing NCT02585960Phase 3CompletedBaxalta now part of ShireStarted 2015
A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A NCT02615691Phase 3CompletedBaxalta now part of ShireStarted 2015
BAX 855 Pediatric Study NCT02210091Phase 3CompletedBaxalta now part of ShireStarted 2014
An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A NCT02172950Phase 3CompletedCSL BehringStarted 2014
Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A NCT02137850Phase 3CompletedNovo Nordisk A/SStarted 2014
Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A NCT02093897Phase 3CompletedCSL BehringStarted 2014
BAX 855 Continuation NCT01945593Phase 3CompletedBaxalta now part of ShireStarted 2013
A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A NCT01731600Phase 3CompletedNovo Nordisk A/SStarted 2013
Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A. NCT01489111Phase 3CompletedNovo Nordisk A/SStarted 2012
Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A NCT01480180Phase 3CompletedNovo Nordisk A/SStarted 2012
Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A NCT01138501Phase 3CompletedNovo Nordisk A/SStarted 2010
Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015 NCT00984126Phase 3CompletedNovo Nordisk A/SStarted 2009
Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects NCT00840086Phase 3CompletedNovo Nordisk A/SStarted 2009

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.

Visit Pharma Observatory

Phase 3 Hemophilia A trials in Malaysia

Trials started per year

Status

Top lead sponsors

Top conditions

Trials

Recently changed trials

Go deeper on Pharma Observatory